131 related articles for article (PubMed ID: 37874926)
1. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor.
Lin F; Jacqueline Kwong W; Pan I; Ye X; Dai D; Tap W
Oncologist; 2024 Apr; 29(4):e535-e543. PubMed ID: 37874926
[TBL] [Abstract][Full Text] [Related]
2. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
Dharmani C; Wang E; Salas M; McCabe C; Diggs A; Choi Y; Jiang J; Keedy VL
Future Oncol; 2022 Apr; 18(13):1595-1607. PubMed ID: 35105158
[TBL] [Abstract][Full Text] [Related]
3. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
Van De Sande M; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; Healey JH
Acta Orthop; 2021 Aug; 92(4):493-499. PubMed ID: 33977825
[TBL] [Abstract][Full Text] [Related]
4. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
Healey JH; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; van de Sande M
Clin Orthop Relat Res; 2023 Jan; 481(1):107-116. PubMed ID: 36001000
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
[TBL] [Abstract][Full Text] [Related]
6. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
7. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
Monestime S; Lazaridis D
Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
[TBL] [Abstract][Full Text] [Related]
8. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
9. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
[TBL] [Abstract][Full Text] [Related]
10. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
11. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
12. Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients.
Helming A; Hansford B; Beckett B
Skeletal Radiol; 2022 May; 51(5):1085-1091. PubMed ID: 34586485
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
[TBL] [Abstract][Full Text] [Related]
14. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
[TBL] [Abstract][Full Text] [Related]
15. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
Future Oncol; 2024 Feb; ():. PubMed ID: 38380590
[TBL] [Abstract][Full Text] [Related]
16. Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team.
McCabe C; Wright H; Polson K; Wagner AJ
Orphanet J Rare Dis; 2023 Oct; 18(1):313. PubMed ID: 37805596
[TBL] [Abstract][Full Text] [Related]
17. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).
Tap W
Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
[TBL] [Abstract][Full Text] [Related]
19. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
20. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
